GOG 0218
Landmark clinical trial that established the role of bevacizumab in combination with carboplatin and paclitaxel for advanced ovarian cancer.
Full Definition
GOG 0218 was a pivotal phase III randomized controlled trial conducted by the Gynecologic Oncology Group that investigated the addition of bevacizumab to standard chemotherapy in patients with advanced ovarian, fallopian tube, or peritoneal cancer. The study demonstrated improved progression-free survival when bevacizumab was added to carboplatin and paclitaxel and continued as maintenance therapy. This trial established bevacizumab as a standard treatment option for advanced ovarian cancer and significantly influenced current treatment paradigms. The results led to FDA approval of bevacizumab for this indication and are frequently referenced in treatment guidelines.
Usage
Usage note: Always include the numerical identifier when referencing specific GOG protocols.
In Context
- "Based on GOG 0218 results, the oncologist recommended adding bevacizumab to the patient's first-line chemotherapy regimen." — Treatment recommendation
- "The GOG 0218 protocol established the standard for bevacizumab use in newly diagnosed advanced ovarian cancer." — Literature review